CollPlant Biotechnologies (CLGN) Research & Development (2017 - 2026)
CollPlant Biotechnologies' (CLGN) quarterly Research & Development came in at $1.7 million in Q1 2026, down 20.29% YoY from $2.1 million in Q1 2025, and down 15.25% on a QoQ basis from $2.0 million in Q4 2025.
CollPlant Biotechnologies (CLGN) Research & Development (2017 - 2026) Analysis & Trends
CollPlant Biotechnologies (CLGN) has 10 years of Research & Development data on file, last reported at $1.7 million in Q1 2026.
- Quarterly Research & Development fell 20.29% year-over-year to $1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.8 million (down 24.03% YoY) and the FY2025 annual result came in at $8.2 million, down 22.14% from the prior year.
- Research & Development slipped to $1.7 million in Q1 2026, from $2.0 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $3.1 million in Q4 2023 to a low of $1.7 million in Q1 2026.
- A 5-year average of $2.4 million and a median of $2.5 million in 2024 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development surged 45.55% — and 2025, when it slipped 27.19%.
- Tracing CLGN's Research & Development over 5 years: stood at $2.6 million in 2022, then rose by 18.05% to $3.1 million in 2023, then retreated by 18.31% to $2.5 million in 2024, then fell by 22.14% to $2.0 million in 2025, then dropped by 15.25% to $1.7 million in 2026.
- The last three Research & Development figures came in at $1.7 million (Q1 2026), $2.0 million (Q4 2025), and $2.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | CollPlant Biotechnologies | 4.13 Mn | 4.13 Mn | -243,000.00 | 1.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 30, 2026 | 1.68 Mn |
| Dec 31, 2025 | 1.98 Mn |
| Sep 30, 2025 | 2.09 Mn |
| Jun 30, 2025 | 2.01 Mn |
| Mar 30, 2025 | 2.11 Mn |
| Dec 31, 2024 | 2.54 Mn |
| Sep 30, 2024 | 2.87 Mn |
| Jun 30, 2024 | 2.70 Mn |
| Mar 31, 2024 | 2.41 Mn |
| Dec 31, 2023 | 3.11 Mn |
| Sep 30, 2023 | 2.70 Mn |
| Jun 30, 2023 | 2.57 Mn |
| Mar 31, 2023 | 2.10 Mn |
| Dec 31, 2022 | 2.64 Mn |
| Sep 30, 2022 | 2.78 Mn |
| Jun 30, 2022 | 2.60 Mn |
| Mar 31, 2022 | 2.24 Mn |
| Dec 31, 2021 | 2.19 Mn |
| Sep 30, 2021 | 1.91 Mn |
| Jun 30, 2021 | 1.90 Mn |